MKK4 Inhibitors—Recent Development Status and Therapeutic Potential

MKK4 (mitogen-activated protein kinase kinase 4; also referred to as MEK4) is a dual-specificity protein kinase that phosphorylates and regulates both JNK (c-Jun N-terminal kinase) and p38 MAPK (p38 mitogen-activated protein kinase) signaling pathways and therefore has a great impact on cell proliferation, differentiation and apoptosis. Overexpression of MKK4 has been associated with aggressive cancer types, including metastatic prostate and ovarian cancer and triple-negative breast cancer. In addition, MKK4 has been identified as a key regulator in liver regeneration. Therefore, MKK4 is a promising target both for cancer therapeutics and for the treatment of liver-associated diseases, offering an alternative to liver transplantation. The recent reports on new inhibitors, as well as the formation of a startup company investigating an inhibitor in clinical trials, show the importance and interest of MKK4 in drug discovery. In this review, we highlight the significance of MKK4 in cancer development and other diseases, as well as its unique role in liver regeneration. Furthermore, we present the most recent progress in MKK4 drug discovery and future challenges in the development of MKK4-targeting drugs.

[1]  L. Zender,et al.  Scaffold modified Vemurafenib analogues as highly selective mitogen activated protein kinase kinase 4 (MKK4) inhibitors. , 2022, European journal of medicinal chemistry.

[2]  N. Gray,et al.  Publication Criteria and Requirements for Studies on Protein Kinase Inhibitors─What Is Expected? , 2022, Journal of medicinal chemistry.

[3]  K. Scheidt,et al.  Rational Design, Optimization, and Biological Evaluation of Novel MEK4 Inhibitors against Pancreatic Adenocarcinoma. , 2021, ACS medicinal chemistry letters.

[4]  E. Verdaguer,et al.  Dual Mkk4 and Mkk7 Gene Deletion in Adult Mouse Causes an Impairment of Hippocampal Immature Granule Cells , 2021, International journal of molecular sciences.

[5]  P. Jänne,et al.  Kinase drug discovery 20 years after imatinib: progress and future directions , 2021, Nature Reviews Drug Discovery.

[6]  L. Zender,et al.  Design and synthesis of 1H-pyrazolo[3,4-b]pyridines targeting mitogen-activated protein kinase kinase 4 (MKK4) - A promising target for liver regeneration. , 2021, European journal of medicinal chemistry.

[7]  Zhi-wen Zhang,et al.  A new prognosis prediction model combining TNM stage with MAP2K4 and JNK in postoperative pancreatic cancer patients. , 2020, Pathology, research and practice.

[8]  M. Pellegrini,et al.  The role of MKK4 in T‐cell development and immunity to viral infections , 2020, Immunology and cell biology.

[9]  L. Zender,et al.  From off-to on-target: New BRAF-inhibitor-template-derived compounds selectively targeting mitogen activated protein kinase kinase 4 (MKK4). , 2020, European journal of medicinal chemistry.

[10]  S. Laufer,et al.  Design and synthesis of novel fluorescently labeled analogs of vemurafenib targeting MKK4. , 2020, European journal of medicinal chemistry.

[11]  H. Nishina,et al.  Hepatocyte Mitogen‐Activated Protein Kinase Kinase 7 Contributes to Restoration of the Liver Parenchyma Following Injury in Mice , 2020, Hepatology.

[12]  A. Poso,et al.  The autoinhibited state of MKK4: Phosphorylation, putative dimerization and R134W mutant studied by molecular dynamics simulations , 2020, Computational and structural biotechnology journal.

[13]  N. Gray,et al.  Discovery of Covalent MKK4/7 Dual Inhibitor. , 2020, Cell chemical biology.

[14]  Conrad C. Huang,et al.  UCSF ChimeraX: Structure visualization for researchers, educators, and developers , 2020, Protein science : a publication of the Protein Society.

[15]  K. Scheidt,et al.  Non-'classical' MEKs: A review of MEK3-7 inhibitors. , 2020, Bioorganic & medicinal chemistry letters.

[16]  P. Sorger,et al.  Leveraging Compound Promiscuity to Identify Targetable Cysteines within the Kinome. , 2019, Cell chemical biology.

[17]  M. Homma,et al.  Prenylated quinolinecarboxylic acid derivative prevents neuronal cell death through inhibition of MKK4 , 2019, Biochemical pharmacology.

[18]  Ximing J. Yang,et al.  Genistein treatment duration effects biomarkers of cell motility in human prostate , 2019, PloS one.

[19]  Matthew R. Clutter,et al.  Synthesis and Biological Evaluation of 3‐Arylindazoles as Selective MEK4 Inhibitors , 2019, ChemMedChem.

[20]  P. Kamath,et al.  Burden of liver diseases in the world. , 2019, Journal of hepatology.

[21]  J. Brognard,et al.  Orange is the new black: Kinases are the new master regulators of tumor suppression , 2018, IUBMB life.

[22]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[23]  R. Libby,et al.  Mkk4 and Mkk7 are important for retinal development and axonal injury-induced retinal ganglion cell death , 2018, bioRxiv.

[24]  Ton Wang,et al.  BRAF and MEK Inhibitors: Use and Resistance in BRAF-Mutated Cancers , 2018, Drugs.

[25]  Huafeng Pan,et al.  MicroRNA‑136 inhibits prostate cancer cell proliferation and invasion by directly targeting mitogen‑activated protein kinase kinase 4. , 2018, Molecular medicine reports.

[26]  P. Poulikakos,et al.  New perspectives for targeting RAF kinase in human cancer , 2017, Nature Reviews Cancer.

[27]  Y. Jang,et al.  Sensitivity of TP53‐Mutated Cancer Cells to the Phytoestrogen Genistein Is Associated With Direct Inhibition of Plk1 Activity , 2017, Journal of cellular physiology.

[28]  Chuandong Wang,et al.  MicroRNA-145 attenuates TNF-α-driven cartilage matrix degradation in osteoarthritis via direct suppression of MKK4 , 2017, Cell Death and Disease.

[29]  Ying Cheng,et al.  Current Development Status of MEK Inhibitors , 2017, Molecules.

[30]  J. Kurie,et al.  MKK4 activates non-canonical NFκB signaling by promoting NFκB2-p100 processing. , 2017, Biochemical and biophysical research communications.

[31]  Kristine K Deibler,et al.  A Chemical Probe Strategy for Interrogating Inhibitor Selectivity Across the MEK Kinase Family. , 2017, ACS chemical biology.

[32]  A. Canbay,et al.  Epidemiology of nonalcoholic steatohepatitis and hepatocellular carcinoma , 2016, Clinical liver disease.

[33]  S. Lim,et al.  Dehydroglyasperin C suppresses TPA‐induced cell transformation through direct inhibition of MKK4 and PI3K , 2016, Molecular carcinogenesis.

[34]  S. González,et al.  Mechanisms of Photoaging and Cutaneous Photocarcinogenesis, and Photoprotective Strategies with Phytochemicals , 2015, Antioxidants.

[35]  E. Kohn,et al.  The MAPK pathway across different malignancies: A new perspective , 2014, Cancer.

[36]  R. Bergan,et al.  Mitogen-Activated Protein Kinase Kinase 4 (MAP2K4) Promotes Human Prostate Cancer Metastasis , 2014, PloS one.

[37]  K. Song,et al.  A Protoberberine Derivative HWY336 Selectively Inhibits MKK4 and MKK7 in Mammalian Cells: The Importance of Activation Loop on Selectivity , 2014, PloS one.

[38]  Henggui Zhang,et al.  Mkk4 Is a Negative Regulator of the Transforming Growth Factor Beta 1 Signaling Associated With Atrial Remodeling and Arrhythmogenesis With Age , 2014, Journal of the American Heart Association.

[39]  Te-Sheng Chang.  Isolation, Bioactivity, and Production of ortho-Hydroxydaidzein and ortho-Hydroxygenistein , 2014, International journal of molecular sciences.

[40]  B. Katzenellenbogen,et al.  Mechanisms enforcing the estrogen receptor β selectivity of botanical estrogens , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[41]  Delong Liu,et al.  MEK and the inhibitors: from bench to bedside , 2013, Journal of Hematology & Oncology.

[42]  M. Manns,et al.  A Direct In Vivo RNAi Screen Identifies MKK4 as a Key Regulator of Liver Regeneration , 2013, Cell.

[43]  Hong-Gang Wang,et al.  Sphingolipids: regulators of crosstalk between apoptosis and autophagy , 2013, Journal of Lipid Research.

[44]  S. Lim,et al.  Antioxidant activities of licorice-derived prenylflavonoids , 2012, Nutrition research and practice.

[45]  T. Kinoshita,et al.  Crystal and solution structures disclose a putative transient state of mitogen-activated protein kinase kinase 4. , 2012, Biochemical and biophysical research communications.

[46]  A. Jemal,et al.  Cancer treatment and survivorship statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[47]  M. Taura,et al.  Antitumor effect of berberine against primary effusion lymphoma via inhibition of NF‐κB pathway , 2012, Cancer science.

[48]  Scott M Lippman,et al.  Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy , 2012, Expert opinion on therapeutic targets.

[49]  Yan Shi,et al.  Berberine Induces Caspase-Independent Cell Death in Colon Tumor Cells through Activation of Apoptosis-Inducing Factor , 2011, PloS one.

[50]  S. Chun,et al.  Apoptotic Effects of Genistein, Biochanin-A and Apigenin on LNCaP and PC-3 Cells by p21 through Transcriptional Inhibition of Polo-like Kinase-1 , 2011, Journal of Korean medical science.

[51]  J. Rundhaug,et al.  The role of the EP receptors for prostaglandin E2 in skin and skin cancer , 2011, Cancer and Metastasis Reviews.

[52]  Yanan Yang,et al.  Map2k4 Functions as a Tumor Suppressor in Lung Adenocarcinoma and Inhibits Tumor Cell Invasion by Decreasing Peroxisome Proliferator-Activated Receptor γ2 Expression , 2011, Molecular and Cellular Biology.

[53]  H. Nishina,et al.  Stress-activated protein kinase MKK7 regulates axon elongation in the developing cerebral cortex , 2011, Neuroscience Research.

[54]  A. Bode,et al.  7,3′,4′-Trihydroxyisoflavone, a Metabolite of the Soy Isoflavone Daidzein, Suppresses Ultraviolet B-induced Skin Cancer by Targeting Cot and MKK4* , 2011, The Journal of Biological Chemistry.

[55]  T. Kinoshita,et al.  Crystal structures of MKK4 kinase domain reveal that substrate peptide binds to an allosteric site and induces an auto-inhibition state. , 2010, Biochemical and biophysical research communications.

[56]  N. Kang,et al.  Cocoa polyphenols suppress TNF-α-induced vascular endothelial growth factor expression by inhibiting phosphoinositide 3-kinase (PI3K) and mitogen-activated protein kinase kinase-1 (MEK1) activities in mouse epidermal cells , 2010, British Journal of Nutrition.

[57]  A. Shiau,et al.  Licorice and licochalcone-A induce autophagy in LNCaP prostate cancer cells by suppression of Bcl-2 expression and the mTOR pathway. , 2009, Journal of agricultural and food chemistry.

[58]  Ximing J. Yang,et al.  MEK4 function, genistein treatment, and invasion of human prostate cancer cells. , 2009, Journal of the National Cancer Institute.

[59]  Xiao-feng Yan,et al.  Inhibitory effects of flavonoids extracted from licorice on lipopolysaccharide-induced acute pulmonary inflammation in mice. , 2009, International immunopharmacology.

[60]  T. Kwon,et al.  Hepatoprotective Activity of Licorice Water Extract against Cadmium-induced Toxicity in Rats , 2007, Evidence-based complementary and alternative medicine : eCAM.

[61]  Connie B. Lin,et al.  Nondenatured Soy Extracts Reduce UVB‐induced Skin Damage via Multiple Mechanisms , 2008, Photochemistry and photobiology.

[62]  A. Bode,et al.  Myricetin suppresses UVB-induced skin cancer by targeting Fyn. , 2008, Cancer research.

[63]  T. Kinoshita,et al.  Protein purification and preliminary crystallographic analysis of human Lyn tyrosine kinase. , 2008, Protein expression and purification.

[64]  C. Takimoto,et al.  Dietary genistein inhibits metastasis of human prostate cancer in mice. , 2008, Cancer research.

[65]  Mindy I. Davis,et al.  A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.

[66]  B. McColl,et al.  Targeted Deletion of the Mitogen-Activated Protein Kinase Kinase 4 Gene in the Nervous System Causes Severe Brain Developmental Defects and Premature Death , 2007, Molecular and Cellular Biology.

[67]  Wei Chen,et al.  Differential regulation and properties of MAPKs , 2007, Oncogene.

[68]  O. Rath,et al.  MAP kinase signalling pathways in cancer , 2007, Oncogene.

[69]  E. Birney,et al.  Patterns of somatic mutation in human cancer genomes , 2007, Nature.

[70]  C. Tournier,et al.  Physiological roles of MKK4 and MKK7: insights from animal models. , 2006, Biochimica et biophysica acta.

[71]  R. Bergan,et al.  MAPKAPK2 and HSP27 are downstream effectors of p38 MAP kinase-mediated matrix metalloproteinase type 2 activation and cell invasion in human prostate cancer , 2006, Oncogene.

[72]  S. Katiyar,et al.  Grape seed proanthocyanidins inhibit UV-radiation-induced oxidative stress and activation of MAPK and NF-kappaB signaling in human epidermal keratinocytes. , 2006, Free radical biology & medicine.

[73]  V. Velculescu,et al.  Homozygous deletion of MKK4 in ovarian serous carcinoma , 2006, Cancer biology & therapy.

[74]  D. Heber,et al.  Antibacterial compounds from Glycyrrhiza uralensis. , 2006, Journal of natural products.

[75]  Andrew D. Yates,et al.  Somatic mutations of the protein kinase gene family in human lung cancer. , 2005, Cancer research.

[76]  W. Hong,et al.  Response of Non–Small Cell Lung Cancer Cells to the Inhibitors of Phosphatidylinositol 3-Kinase/Akt- and MAPK Kinase 4/c-Jun NH2-Terminal Kinase Pathways: An Effective Therapeutic Strategy for Lung Cancer , 2005, Clinical Cancer Research.

[77]  J. Ptak,et al.  Colorectal cancer: Mutations in a signalling pathway , 2005, Nature.

[78]  H. Saito,et al.  Conserved docking site is essential for activation of mammalian MAP kinase kinases by specific MAP kinase kinase kinases. , 2005, Molecular cell.

[79]  Xiaoke Huang,et al.  Genistein inhibits p38 map kinase activation, matrix metalloproteinase type 2, and cell invasion in human prostate epithelial cells. , 2005, Cancer research.

[80]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[81]  L. Trümper.  From bench to bedside , 2005, Medizinische Klinik.

[82]  J. Warmus,et al.  Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition , 2004, Nature Structural &Molecular Biology.

[83]  Yong Pan,et al.  Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors , 2004, Oncogene.

[84]  C. Lynch,et al.  Improved survival of follicular lymphoma patients in the surveillance, epidemiology, and end-results (SEER) program , 2004 .

[85]  N. Chow,et al.  Genistein arrests hepatoma cells at G2/M phase: involvement of ATM activation and upregulation of p21waf1/cip1 and Wee1. , 2004, Biochemical pharmacology.

[86]  H. Kishida,et al.  A licorice ethanolic extract with peroxisome proliferator-activated receptor-gamma ligand-binding activity affects diabetes in KK-Ay mice, abdominal obesity in diet-induced obese C57BL mice and hypertension in spontaneously hypertensive rats. , 2003, The Journal of nutrition.

[87]  Lee Bardwell,et al.  A Docking Site in MKK4 Mediates High Affinity Binding to JNK MAPKs and Competes with Similar Docking Sites in JNK Substrates* , 2003, Journal of Biological Chemistry.

[88]  M. John,et al.  Role of c‐jun N‐terminal kinase in the induced release of GM‐CSF, RANTES and IL‐8 from human airway smooth muscle cells , 2003, British journal of pharmacology.

[89]  N. Kennedy,et al.  Role of JNK in Tumor Development , 2003, Cell cycle.

[90]  T. Hunter,et al.  The Protein Kinase Complement of the Human Genome , 2002, Science.

[91]  A. Montag,et al.  Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. , 2002, Cancer research.

[92]  M. Gaestel,et al.  In the Cellular Garden of Forking Paths: How p38 MAPKs Signal for Downstream Assistance , 2002, Biological chemistry.

[93]  P. Cohen.  Protein kinases — the major drug targets of the twenty-first century? , 2002, Nature reviews. Drug discovery.

[94]  Huitu Liu,et al.  MAPK signal pathways in the regulation of cell proliferation in mammalian cells , 2002, Cell Research.

[95]  D. Bozyczko‐Coyne,et al.  Targeting the JNK pathway for therapeutic benefit in CNS disease. , 2002, Current drug targets. CNS and neurological disorders.

[96]  R. Flavell,et al.  MKK7 is an essential component of the JNK signal transduction pathway activated by proinflammatory cytokines. , 2001, Genes & development.

[97]  Ximing J. Yang,et al.  Mitogen-activated protein kinase kinase 4 metastasis suppressor gene expression is inversely related to histological pattern in advancing human prostatic cancers. , 2001, Cancer research.

[98]  W. Stetler-Stevenson,et al.  Proteases in invasion: matrix metalloproteinases. , 2001, Seminars in cancer biology.

[99]  M. Cobb,et al.  Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. , 2001, Endocrine reviews.

[100]  P. Cohen,et al.  Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7. , 2000, The Biochemical journal.

[101]  R. Davis,et al.  Signal Transduction by the JNK Group of MAP Kinases , 2000, Cell.

[102]  A. Cuenda.  Mitogen-activated protein kinase kinase 4 (MKK4). , 2000, The international journal of biochemistry & cell biology.

[103]  J. K. Lee,et al.  Dynamic expression of SEK1 suggests multiple roles of the gene during embryogenesis and in adult brain of mice. , 1999, Brain research. Molecular brain research.

[104]  P. Cohen,et al.  Synergistic activation of SAPK1/JNK1 by two MAP kinase kinases in vitro , 1998, Current Biology.

[105]  M. Karin,et al.  JNKK1 organizes a MAP kinase module through specific and sequential interactions with upstream and downstream components mediated by its amino-terminal extension. , 1998, Genes & development.

[106]  T. Sasaki,et al.  Impaired TCR-mediated apoptosis and Bcl-XL expression in T cells lacking the stress kinase activator SEK1/MKK4. , 1998, Journal of immunology.

[107]  W. Lee,et al.  Genistein-induced G2/M arrest is associated with the inhibition of cyclin B1 and the induction of p21 in human breast carcinoma cells. , 1998, International journal of oncology.

[108]  L. Zon,et al.  SEK1 deficiency reveals mitogen-activated protein kinase cascade crossregulation and leads to abnormal hepatogenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[109]  R. Hruban,et al.  Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. , 1998, Cancer research.

[110]  B. Su,et al.  Molecular cloning and characterization of a human protein kinase that specifically activates c-Jun N-terminal kinase. , 1998, Gene.

[111]  R. Xavier,et al.  SEK1/MKK4 is required for maintenance of a normal peripheral lymphoid compartment but not for lymphocyte development. , 1998, Immunity.

[112]  S. Noselli,et al.  MKK7 Is A Stress-activated Mitogen-activated Protein Kinase Kinase Functionally Related to hemipterous * , 1997, The Journal of Biological Chemistry.

[113]  A. Lin,et al.  Identification of c-Jun NH2-terminal Protein Kinase (JNK)-activating Kinase 2 as an Activator of JNK but Not p38* , 1997, The Journal of Biological Chemistry.

[114]  T. Mak,et al.  Impaired CD28-mediated Interleukin 2 Production and Proliferation in Stress Kinase SAPK/ERK1 Kinase (SEK1)/Mitogen-activated Protein Kinase Kinase 4 (MKK4)-deficient T Lymphocytes , 1997, The Journal of experimental medicine.

[115]  R. Davis,et al.  Mitogen-activated protein kinase kinase 7 is an activator of the c-Jun NH2-terminal kinase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[116]  J. Blank,et al.  Characterization of the Mitogen-activated Protein Kinase Kinase 4 (MKK4)/c-Jun NH2-terminal kinase 1 and MKK3/p38 Pathways Regulated by MEK Kinases 2 and 3 , 1997, The Journal of Biological Chemistry.

[117]  S. Barnes,et al.  Genistein inhibits both estrogen and growth factor-stimulated proliferation of human breast cancer cells. , 1996, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[118]  I. Dreosti,et al.  The antioxidant activity of genistein in vitro , 1995 .

[119]  P. Cohen,et al.  Activation of the MAP kinase homologue RK requires the phosphorylation of Thr‐180 and Tyr‐182 and both residues are phosphorylated in chemically stressed KB cells , 1995, FEBS letters.

[120]  M. Karin,et al.  Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2. , 1995, Science.

[121]  Jiahuai Han,et al.  Independent human MAP-kinase signal transduction pathways defined by MEK and MKK isoforms , 1995, Science.

[122]  L. Zon,et al.  Activation of stress-activated protein kinase by MEKK1 phosphorylation of its activator SEK1 , 1994, Nature.

[123]  L. Zon,et al.  Role of SAPK/ERK kinase-1 in the stress-activated pathway regulating transcription factor c-Jun , 1994, Nature.

[124]  A. Franke,et al.  Quantitation of Phytoestrogens in Legumes by HPLC , 1994 .

[125]  C. Riccardi,et al.  The natural tyrosine kinase inhibitor genistein produces cell cycle arrest and apoptosis in Jurkat T-leukemia cells. , 1994, Leukemia research.

[126]  H. Adlercreutz,et al.  Plasma concentrations of phyto-oestrogens in Japanese men , 1993, The Lancet.

[127]  R. Severson,et al.  A prospective study of demographics, diet, and prostate cancer among men of Japanese ancestry in Hawaii. , 1989, Cancer research.

[128]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[129]  T. Hunter,et al.  The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. , 1988, Science.

[130]  M. Shibuya,et al.  Genistein, a specific inhibitor of tyrosine-specific protein kinases. , 1987, The Journal of biological chemistry.

[131]  J. Niedel,et al.  Phorbol diester receptor copurifies with protein kinase C. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[132]  Y Nishizuka,et al.  Direct activation of calcium-activated, phospholipid-dependent protein kinase by tumor-promoting phorbol esters. , 1982, The Journal of biological chemistry.